
|Videos|August 3, 2020
ASRS 2020: Dexamethasone intracameral drug-delivery suspension in vitreoretinal surgery inflammation
Author(s)Alex Delaney-Gesing
Daniel F. Kiernan, MD, FACS, speaks on the key findings and take-aways of his presentation "Dexamethasone intracameral drug-delivery suspension for inflammation associated with vitreoretinal surgery."
Advertisement
Daniel F. Kiernan, MD, FACS, speaks with Ophthalmology Times®' David Hutton on the key findings and take-aways from his presentation, "Dexamethasone intracameral drug-delivery suspension for inflammation associated with vitreoretinal surgery," during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation
2
Ophthalmic drug shortages more frequent, longer lasting than average
3
NovaBridge, Visara report positive phase 2a results for dual VEGF-A/ANG-2 inhibitor VIS-101
4
Genetic Retinoblastoma Risk Stratified by Age Among Patients with Metachronous Bilateral Conversion
5


































